Cellular Biomedicine Group, a clinical-stage biopharmaceutical company that develops immunotherapies for cancer and stem cell therapies for degenerative diseases, recently partnered with GE Healthcare to build a platform to produce therapies at scale for clinical trials. Aims to solve challenge of developing enough genetically modified cells to test products on large populations.
Joseph Wu Director of the Stanford Cardiovascular Institute and Professor of Medicine and Radiology at Stanford University, discusses the rise of engineered cell and tissue products for use in patients. While these products are now technically advanced and better suited for the clinic, there continues to be issues around patient safety that need to be monitored and mitigated for routine use and mass production.
Gain access to free tools and resources from AABME, an initiative designed to stimulate biomedical innovation by bringing together and providing resources to the biomedical engineering community.
For the first time, the revolutionary gene-editing technology called CRISPR-Cas9 was used to repair a disease-causing genetic flaw in viable human embryos and prevent the mutation from being passed to future generations.
A new nuclease inhibitor drug program could lead to the commercialization of novel DNA damage response (DDR) treatments for female breast, ovarian, and other types of cancers.
Rice University researchers have found that breaking down a virus’s tough outer shell creates nanoparticles that could improve the delivery of chemotherapies and other medicines to diseased cells.
Dr. Patrick Hanley, assistant research professor of pediatrics in the Center for Cancer and Immunology research at the Children’s Research Institute in Washington D.C. and director of the Good Manufacturing Practices cell therapy laboratory at Children’s National Health System, on the new developments in the design and manufacturing for T cell therapies. He discussed ways in which technology can help simplify the methodologies and bring consistency and scalability to cell manufacturing.
Georgia Tech Engineers created an organization to develop standards and production processes designed to mass produce life-saving cell-based therapeutics at affordable prices. Via AABME.
A new ultrasound technique that manipulates immune cells from outside the body could be the future of cancer care.
Researchers discover new molecular linker that orients targeting antibodies to help nucleic-acid filled particles reach target cells via AABME
Testing drugs against patients’ cancer cells—without subjecting patients to chemotherapy—could lead to better, faster treatment.
A new breakthrough in anti-aging research could lead to gene and stem cell therapies that turn back the hands of time.
Researchers at the University of Pittsburgh’s Center for Cellular and Molecular Engineering have developed a small bioreactor that grows constructs of bone and cartilage in a single chamber.
A combined bioreactor and cell culture analyzer automatically monitors and adjusts growing conditions on 48 different cell cultures.
Regenerative medicine searches for ways to move into larger tests and commercial products.